Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Human Blastoid-Based Platform for Post-Implantation IVF Optimization and Therapeutic Screening

Objetivo

Since the first successful IVF birth in 1978, the technology has become a cornerstone of assisted
reproduction, driven by the trend toward delayed parenthood. While IVF now accounts for roughly
5% of births in Europe, its overall efficiency remains low, with only about 25% of cycles resulting in a
live birth. A major bottleneck is the high rate of failure during implantation. Due to the limited
availability of human embryos and ethical restrictions, IVF optimization has historically relied on
mouse models. However, while pre-implantation development is similar between mice and humans,
their post-implantation trajectories diverge significantly, limiting their translational relevance. This
highlights the urgent need for a reliable, ethical, and predictive model of early human development
after implantation. Under the ERC-CoG program, we developed human blastoids, blastocyst-like
structures that accurately mimic key features of pre-implantation human embryogenesis. The present ERC-PoC project will translate
this platform into a pre-commercial application by screening compounds to improve IVF outcomes.
Our expected deliverables include: (i) a validated blastoid-based screening platform, (ii) patented natural compounds with therapeutic potential for IVF, and (iii) a
business and IP framework for investors, partners, and funding bodies.

Ámbito científico (EuroSciVoc)

Este proyecto aún no se ha clasificado con EuroSciVoc.
Sugiera los ámbitos científicos que considere más relevantes y ayúdenos a mejorar nuestro servicio de clasificación.

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) ERC-2025-POC

Ver todos los proyectos financiados en el marco de esta convocatoria

Institución de acogida

INSTITUT FUER MOLEKULARE BIOTECHNOLOGIE GMBH
Aportación neta de la UEn
€ 150 000,00
Dirección
DR BOHRGASSE 3
1030 Wien
Austria
Región
Ostösterreich Wien Wien
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
Sin datos

Beneficiarios (1)